SEC Stock Data Quick Answer Xilio Therapeutics, Inc. reported Stockholders Equity of $35.27 million for fiscal year 2025. Xilio Therapeutics, Inc. Stockholders Equity — Annual History Fiscal Year Stockholders Equity YoY Change 2025 $35.27M +100.4% 2024 $17.60M -52.2% 2023 $36.83M -65.1% 2022 $105.65M -43.0% 2021 $185.43M +322.6% 2020 -$83.29M -182.1% 2019 -$29.52M — Quarterly Stockholders Equity Quarter Ending … Read more
Quick Answer Xilio Therapeutics, Inc. reported Cash and Equivalents of $137.53 million for fiscal year 2025. Xilio Therapeutics, Inc. Cash and Equivalents — Annual History Fiscal Year Cash and Equivalents YoY Change 2025 $137.53M +148.7% 2024 $55.29M +23.7% 2023 $44.70M -62.9% 2022 $120.39M -39.2% 2021 $198.05M +929.5% 2020 $19.24M — Quarterly Cash and Equivalents Quarter … Read more
Quick Answer Xilio Therapeutics, Inc. reported Total Assets of $154.69 million for fiscal year 2025. Xilio Therapeutics, Inc. Total Assets — Annual History Fiscal Year Total Assets YoY Change 2025 $154.69M +117.6% 2024 $71.08M +16.7% 2023 $60.93M -56.2% 2022 $139.16M -36.2% 2021 $218.06M +500.4% 2020 $36.32M — Quarterly Total Assets Quarter Ending Total Assets YoY … Read more
Quick Answer Xilio Therapeutics, Inc. reported Diluted EPS of $4.19 per share (loss) for fiscal year 2025. Xilio Therapeutics, Inc. Diluted EPS — Annual History Fiscal Year Diluted EPS YoY Change 2025 -$4.19 +72.5% 2024 -$15.24 -448.2% 2023 -$2.78 +13.7% 2022 -$3.22 +76.2% 2021 -$13.52 +87.2% 2020 -$105.42 — Quarterly Diluted EPS Quarter Ending Diluted … Read more
Quick Answer Xilio Therapeutics, Inc. reported Net Income of -$35.04 million for fiscal year 2025. Xilio Therapeutics, Inc. Net Income — Annual History Fiscal Year Net Income YoY Change 2025 -$35.04M +39.8% 2024 -$58.24M +23.8% 2023 -$76.40M +13.4% 2022 -$88.22M -16.4% 2021 -$75.80M -37.3% 2020 -$55.22M — Quarterly Net Income Quarter Ending Net Income YoY … Read more
Quick Answer Xilio Therapeutics, Inc. reported Revenue (ASC 606) of $43.77 million for fiscal year 2025. Xilio Therapeutics, Inc. Revenue (ASC 606) — Annual History Fiscal Year Revenue (ASC 606) YoY Change 2025 $43.77M +589.9% 2024 $6.34M — Quarterly Revenue (ASC 606) Quarter Ending Revenue (ASC 606) YoY QoQ September 30, 2025 $19.07M +742.5% +135.8% … Read more
Quick Answer Xilio Therapeutics, Inc. reported Total Revenue of $43.77 million for fiscal year 2025. Xilio Therapeutics, Inc. Total Revenue — Annual History Fiscal Year Total Revenue YoY Change 2025 $43.77M +589.9% 2024 $6.34M — Quarterly Total Revenue Quarter Ending Total Revenue YoY QoQ September 30, 2025 $19.07M +742.5% +135.8% June 30, 2025 $8.08M +243.0% … Read more
Quick Answer Xilio Therapeutics, Inc. reported Total Revenue of $43.77 million for fiscal year 2025. Xilio Therapeutics, Inc. — Key Financials by Year Metric 2025 2024 2023 2022 2021 2020 Total Revenue $43.77M+589.9% $6.34M — — — — Revenue (ASC 606) $43.77M+589.9% $6.34M — — — — Net Income -$35.04M+39.8% -$58.24M+23.8% -$76.40M+13.4% -$88.22M-16.4% -$75.80M-37.3% -$55.22M … Read more
Quick Answer Xenous Holdings, Inc. reported Shares Outstanding of 760.25 million shares for fiscal year 2025. Xenous Holdings, Inc. Shares Outstanding — Annual History Fiscal Year Shares Outstanding YoY Change 2025 760.25M +0.0% 2024 760.25M +0.0% 2023 760.25M +0.0% 2022 760.25M +0.0% 2021 760.25M +0.0% 2020 760.25M +0.0% 2019 760.25M +0.0% 2018 760.25M -43.1% 2017 … Read more
Quick Answer Xenous Holdings, Inc. reported Operating Income of -$63.9 thousand for fiscal year 2020. Xenous Holdings, Inc. Operating Income — Annual History Fiscal Year Operating Income YoY Change 2020 -$63.9K +69.7% 2019 -$211.0K -15.5% 2018 -$182.7K -918.5% 2017 -$17.9K +27.1% 2016 -$24.6K -160.9% 2015 -$9.4K — Quarterly Operating Income Quarter Ending Operating Income YoY … Read more